Literature DB >> 21772098

[Efficacy of oxycodone against anti-cancer agent-induced pain in breast cancer patients during adjuvant treatment before and after surgery].

Kenichi Inoue1, Shigenari Nagai, Shihori Kaneko, Sayaka Uchida, Yuji Hayashi, Toru Higuchi, Takashi Yoshida, Hiroyuki Takei, Toshio Tabei.   

Abstract

Chemotherapeutic agents, especially paclitaxel, and endocrinotherapeutic agents such as aromatase inhibitors and antiestrogen, can induce seriously painful symptoms in breast cancer patients during adjuvant treatment before and after surgery. We report five clinical cases in which oxycodone was effective against pain induced by anti-cancer agents during adjuvant treatment. Paclitaxel was used as the anti-cancer agent in each of the five patients. Aromatase inhibitors and anti-estrogen were administered to one and three patients, respectively. The daily dose of controlled-release oxycodone ranged from 10 mg to 270 mg, but none of the patients dropped out due to adverse events caused by oxycodone. Pain intensity measured by NRS decreased to less than 3 out of 10, compared to the baseline in every patient except for one. Oxycodone may be effective against anti-cancer agent-induced pain. In addition, appropriate assessment and management of pain may be crucial for breast cancer patients during adjuvant treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21772098

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  Use of oxycodone in pain management.

Authors:  Mohammad Moradi; Sara Esmaeili; Saeed Shoar; Saeid Safari
Journal:  Anesth Pain Med       Date:  2012-04-01

2.  Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.

Authors:  Mamoru Takada; Toru Higuchi; Katsunori Tozuka; Hiroyuki Takei; Masayuki Haruta; Junko Watanabe; Fumio Kasai; Kenichi Inoue; Masafumi Kurosumi; Masaru Miyazaki; Aiko Sato-Otsubo; Seishi Ogawa; Yasuhiko Kaneko
Journal:  BMC Cancer       Date:  2013-05-16       Impact factor: 4.430

3.  Analgesic effect of AG490, a Janus kinase inhibitor, on oxaliplatin-induced acute neuropathic pain.

Authors:  Shuang-Feng Li; Bi-Shan Ouyang; Xin Zhao; Ya-Ping Wang
Journal:  Neural Regen Res       Date:  2018-08       Impact factor: 5.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.